Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Low-dose RSV mRNA vaccine · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| Sinovac RSV mRNA vaccine low-dose group | EXPERIMENTAL | Participants will receive one dose of low-dose lyophilized RSV mRNA vaccine. |
| Sinovac RSV mRNA vaccine high-dose group | EXPERIMENTAL | Participants will receive one dose of high-dose lyophilized RSV mRNA vaccine. |
| Placebo control group | PLACEBO_COMPARATOR | Participants will receive one dose of normal saline. |
| Name | Type | Description |
|---|---|---|
| Low-dose RSV mRNA vaccine | BIOLOGICAL | One dose of RSV mRNA vaccine in low dosage |
| High-dose RSV mRNA vaccine | BIOLOGICAL | One dose of RSV mRNA vaccine in high dosage |
| Placebo | OTHER | Participants will receive one dose of normal saline. |
Inclusion Criteria: 1. Participants can understand and voluntarily sign the informed consent form; 2. Able to provide legal identity documents; 3. Healthy individuals aged 18 years and above; 4. Participants of childbearing potential and their sexual partners voluntarily adopt effective contracepti...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Pfizer Inc. | PFE | 7 | PHASE3 | RSVpreF |
| Enanta Pharmaceuticals, Inc. | ENTA | 1 | PHASE2 | zelicapavir |
| Moderna, Inc. | MRNA | 1 | PHASE1 | mRNA-1345, mRNA-1365, Nimenrix |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE1 | Low-dose RSV mRNA vaccine |
| Sanofi SA Sponsored ADR | SNY | 2 | - | Nirsevimab |
| AstraZeneca PLC | AZN | 1 | N/A | Palivizumab/kg |
Low-dose RSV mRNA vaccine is an investigational vaccine being developed for the prevention of respiratory syncytial virus (RSV) infection. It is currently in Phase 1 clinical development and is not yet approved for use. The vaccine is designed to elicit an immune response against RSV.
Low-dose RSV mRNA vaccine is being developed by Sinovac Biotech, Ltd, a biopharmaceutical company traded on the stock exchange under the ticker symbol SVA. The company is conducting clinical trials to evaluate the safety and immunogenicity of this investigational RSV vaccine.
Low-dose RSV mRNA vaccine is currently in Phase 1 clinical development. It is an investigational vaccine and has not received regulatory approval. The Phase 1 trial is designed to assess the safety of the vaccine in healthy volunteers.
Low-dose RSV mRNA vaccine is being evaluated in a Phase 1 clinical trial registered as NCT07418229, titled 'Study to Evaluate the Safety of a Lyophilized RSV mRNA Vaccine'. This randomized, double-blind, placebo-controlled trial is enrolling 60 participants in China and is currently not yet recruiting.
No, Low-dose RSV mRNA vaccine is not FDA approved. It is an investigational vaccine currently in Phase 1 clinical trials. The vaccine has not yet completed the clinical development process required for regulatory approval.